Finally, the authors showed that the beneficial effects of FeSiNTs-siSPAG5 depend on the inhibition of the PI3K/AKT/mTOR signaling, an oncogenic pathway that promotes cancer growth, survival and progression. This evidence concerns the gene AKT1 and cancer.